Product Description
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Influenza, Human
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT01323946 | P2 |
Completed |
Influenza, Human |
2012-06-22 |
2019-03-19 |
Primary Completion Date|Start Date|Study Completion Date|Treatments |
|
| H5N1-013 | P2 |
Terminated |
Influenza, Human |
2012-02-14 |
2025-06-29 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
| NCT00502593 | P2 |
Completed |
Influenza, Human |
2009-12-04 |
2019-03-21 |
Treatments |
|
| NCT00506350 | P2 |
Completed |
Influenza, Human |
2009-10-12 |
2019-03-21 |
Treatments |
|
| NCT00397215 | P2 |
Completed |
Influenza, Human |
2009-09-14 |
2019-06-13 |
Primary Completion Date|Start Date|Study Completion Date|Treatments |
|
| FLU D-PAN H5N1=AS03-032 | P3 |
Completed |
Influenza, Human |
2014-07-24 |
2025-06-27 |
Primary Completion Date|Start Date|Study Completion Date|Treatments |
|
| NCT01379937 | P3 |
Completed |
Influenza, Human |
2012-08-02 |
2019-03-19 |
Treatments |
|
| NCT00652743 | P3 |
Completed |
Influenza, Human |
2011-06-08 |
2019-03-18 |
Treatments |
|
| NCT00812981 | P3 |
Completed |
Influenza, Human |
2009-06-07 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|